Microbiota contribute to skin damage in cancer therapy
New research demonstrates that disruption of EGF receptor signalling allows commensal bacteria to invade hairs and cause skin lesions.
BIOncoTech Therapeutics and MSD combine cancer drugs
Madrid-based RNA specialist Bioncotech Therapeutics has entered into a Phase II clinical trial collaboration with a MSD subsidiary.
Urokinase clears blot clots in stroke patients
Swiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.
Sanofi buys Synthorx Inc for US$2.35bn
Sanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.
Meatable NV raises US$10m in seed funding
Meatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the companys total funding to US$13m.
Big Pharma is cost driver of GAVI
Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine
ImCheck Therapeutics SAS raises 48m
T cell agonist specialist ImCheck Therapeutics will use 48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre amends license agreement with Puma Biotechnology
Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
European circular bioeconomy fund near closing
The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the 250m EU circular bioeconomy fund.
Researchers find new indication for cancer drug
French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.